Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Cytotoxic T lymphocyte cell therapy for post-transplant lymphoproliferative disorder in the central nervous system

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.18
Views: 568

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Prof Mohamad Mohty speaks to ecancer at ASH 2018 about a study looking into cell therapy using cytotoxic T lymphocytes to treat Epstein–Barr virus related post-transplant lymphoproliferative disorder (PTLD) in the central nervous system.

He explains that, until now, if the usual treatment was not a success there was no viable second option.

Prof Mohty reveals that the results of the study have shown a significant response rate of over 60% and also a number of complete remissions.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation